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ABSTRACT
One erythropoietin molecule binds asymmetrically to two identical receptor
monomers via erythropoietin site 1 and site 2, although it is unclear how asymmetry
affects receptor activation and signaling. Here we report the computational design and
experimental validation of two mutant erythropoietin receptors: one that binds only to
erythropoietin site 1 but not site 2, and one that binds only to site 2 but not site 1.
Expression of either mutant receptor alone in Ba/F3 cells cannot elicit a signal in
response to erythropoietin, but when co-expressed, there is a proliferative response and
activation of the JAK2 Stat5 signaling pathway. A truncated erythropoietin receptor with
only one cytosolic tyrosine (Y343), on only one receptor monomer is sufficient for
signaling in response to erythropoietin, regardless of the monomer on which it is located.
The same results apply to having only one conserved juxtamembrane hydrophobic L253
or W258 residue, essential for JAK2 activation, in the full-length receptor dimer. We
conclude that despite asymmetry in the ligand-receptor dimer interaction, both sides are
competent for signaling, and we suggest that the receptors signal equally.
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Introduction
Erythropoietin (Epo) is a cytokine necessary for regulating erythropoiesis (Graber
et al. 1978). Produced primarily by the kidney in adult humans (Jacobson et al. 1957), it
stimulates erythroid progenitor cells to proliferate and terminally differentiate by
interacting with cell surface erythropoietin receptors (EpoRs) to initiate downstream
signaling cascades (Koury et al. 1988). Although EpoR is mainly expressed in
hematopoietic tissues, it is also expressed in vascular endothelial cells (Anagnostou et al.
1994) and tissues of the central nervous system (Liu et al. 1997).
EpoR is a member of the type 1 superfamily of single-transmembrane cytokine
receptors, all of which share conserved fibronectin III-like extracellular subdomains, a
WSXWS motif important for protein folding, and short stretches of conserved
cytoplasmic regions termed Box1 and Box2, while lacking intrinsic protein tyrosine
kinase activity (Bazan 1990). EpoR in particular associates with JAK2, a member of the
Janus kinase family (Witthuhn et al. 1993), following EpoR synthesis in the endoplasmic
reticulum. The EpoR is expressed on the cell surface as a pre-formed receptor homodimer
(Livnah et al. 1999), mediated by the leucine zipper of the transmembrane domain
(Constantinescu, Keren et al. 2001). Binding of Epo to EpoR induces JAK2 activation via
either auto- or trans-phosphorylation of the appended JAK2 molecules, and requires the
presence of three conserved hydrophobic "switch" residues in the EpoRjuxtamembrane
domain, L253, 1257, and W258 (Constantinescu, Huang et al. 2001). JAK2 activation is
necessary for subsequent phosphorylation of up to eight tyrosine residues on the
cytoplasmic segment of each EpoR monomer (Klingmuller 1997). These
phosphotyrosines recruit downstream signaling molecules for intracellular pathways
involving Stat5, Ras/MAPK, and PI3K/Aktl (Miura et al. 1994; Damen, Cutler et al.
1995; Damen, Wakao et al. 1995).
As a monomeric, asymmetric molecule, Epo employs two different interfaces,
termed site 1 and site 2, to bind to the two monomers of an EpoR homodimer. Site 1 on
Epo is a high affinity binding site, with a KD of 1nM, whereas site 2 has a thousand-fold
lower affinity for the EpoR, with a KD of -1ýM (Philo et al. 1996). Because the EpoR
dimer is comprised of two identical transmembrane proteins, both monomers have the
ability to bind Epo at site 1 and site 2, depending on the order and direction in which the
Epo molecule enters the receptor binding site. A crystal structure of one Epo molecule
bound to two EpoR extracellular ligand binding domains shows that the site 1 interface,
which is characterized by a central hydrophobic binding pocket, contains many more
overall Epo-EpoR contacts than the site 2 interface, whose interacting residues mostly
fall within a subset of the site 1 residues (Syed et al. 1998).
It is hypothesized that the asymmetry of the Epo-EpoR interaction is necessary for
proper orientation of the EpoR monomers to initiate JAK2 activation (Constantinescu,
Huang et al. 2001; Seubert et al. 2003). In this scheme, Epo activates EpoR by
positioning the two EpoR monomers such that the weakly active catalytic site of one
associated JAK2 molecule is adjacent to the critical tyrosine residue in the activation loop
of the second JAK2, thus promoting phosphorylation of the tyrosine and activation of the
second JAK2 to initiate downstream signaling events (Lu et al. 2006). Epo mimetic
peptides activate EpoR by forming symmetric EpoR dimers, although the level of
activation and response achieved by these peptides is inferior to Epo stimulation (Livnah
et al. 1996; Wrighton et al. 1996). This difference suggests that there is an optimal
receptor orientation achieved by the Epo binding interaction. Furthermore, certain
peptides that bind and dimerize EpoR do not induce any receptor activation, consistent
with the notion that receptor dimerization alone is insufficient for receptor activation and
signaling (Livnah et al. 1998). There is also a possibility that the asymmetric interaction
between Epo and the EpoR monomers could translate to differences in each monomer's
contribution to the activation of and signaling by the receptor. In particular, the large
difference in the Epo binding affinities of site 1 and site 2 may be indicative of a
dominant role in the receptor that binds Epo at site 1, or there may be a time delay
between the activation of each receptor. However, it is also possible that despite the
asymmetry of ligand-receptor interaction, the two monomers contribute equally to the
activation and signaling of the EpoR.
Our goal is to systematically explore the mechanism of EpoR activation as a
result of asymmetric interaction with Epo, and to understand the role of contributing
structural elements in each receptor in initiating JAK2 activation and subsequent
signaling. Currently, experimental study of the roles of each individual EpoR monomer in
the Epo-EpoR complex is impossible because the monomers have the same molecular
structure and cannot be selectively tracked or manipulated. Similar problems in the past
have been approached by the construction of "single-chain" dimers, in which a
polypeptide linker connects the C-terminus of one monomer to the N-terminus of another
such that intramolecular dimerization interactions are strongly favored (Robinson et al.
1996). To implement such a strategy here would require that the linker pass through the
membrane and still would be unlikely to cause Epo to bind in a unique orientation, and
thus we adopted a different approach. Here, we have computationally designed a pair of
EpoRs mutant in their ability to bind Epo at only site 1 or site 2. Expressed alone, these
mutants cannot support proper activation and signaling in response to Epo, but when co-
expressed, the response to Epo is restored to nearly wild-type levels. Using this novel
cell-based, heterodimeric EpoR system, we generated EpoR mutants to study the
contribution of several structural components when present on either the site 1 or site 2-
binding monomer. A study of EpoR with such fine control has not been possible with
previously existing methods, and we believe this study demonstrates the usefulness of
these novel probes as tools for gaining a deeper understanding of other homodimeric
cytokine receptors such as the G-CSF and thrombopoietin receptors.
Results
Computational Design of EpoR Mutants
Our goal was to generate a pair of human EpoRs each able to bind only to either
site 1 or site 2 on Epo, mutants that would allow us to differentiate between the two
receptors in an Epo-binding receptor complex. To design these mutants, we
computationally analyzed mutations at candidate residues in the binding sites of EpoR to
predict changes in Epo binding properties.
From the 1.9-A crystal structure of Epo complexed with the extracellular portion
of wild-type EpoR (PDB ID: 1EER) (Syed et al. 1998), we identified candidate residues
whose mutation could predominantly affect only site 1 or site 2, but not both. Figure la
shows the structure of two EpoR monomers bound to one Epo molecule, with the site 1
and site 2 EpoR interaction regions highlighted in yellow.
Of EpoR residues interacting directly with Epo at site 1 but not site 2, His 114 and
Glu 117 were chosen for initial mutational analysis. His 114 was chosen because previous
work (Radhakrishnan 2007) showed that mutating this residue can significantly alter
binding affinity; the binding affinity of EpoR H114K and EpoR H1 14T to Epo were
reduced several-fold compared to wild-type EpoR. Glu117 was chosen because it forms a
:salt bridge with Epo residue Argl50, a critical site 1 interaction residue. A mutation at
this site could disrupt electrostatic complementarity and thereby reduce binding affinity.
In the site 2-binding EpoR monomer, His114 and Glu 117 are both too far from Epo
residues for direct packing or hydrogen-bonding interactions, although they are
potentially close enough for intermediate-range electrostatic interactions. Thus
computational mutational analyses of the two residues were performed at both site 1 and
site 2 to assess these potential effects.
The site 2 interface contains fewer EpoR residues than site 1, with those at site 2
mostly a subset of those at site 1. We selected EpoR Met150 for our initial mutational
analysis because it makes close contacts at the site 2 interface but not at site 1. Thus, we
hypothesized that an appropriate mutation could disrupt binding to Epo site 2 with less
effect at site 1.
The three selected EpoR residues, Hisll114, Glu117, and Metl50, were each
computationally mutated in turn at either the site 1 or site 2 interfaces and the effect on
binding affinity evaluated, with the goal of identifying mutations that would specifically
alter binding free energy at one site while leaving the other site relatively unaffected. For
each candidate residue at its primary binding site (site 1 for His114 and Glu117, and site
2 for Metl50), mutations to all other amino acids were considered except to cysteine,
proline, and glycine, in order to avoid disulfide bridge interference and changes in
backbone flexibility and conformation. Those amino acids that were predicted to greatly
weaken binding at the primary binding site were then evaluated for binding to the other
Epo site.
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Figure 1. Structures of Epo complexed with wild-type and mutant EpoR dimers. (A)
One monomer of wild-type EpoR binds to Epo at site I while a second wild-type monomer binds
at site 2. The highlighted yellow regions on EpoR distinguish the site 1 and site 2 interaction
residues, which are not mutually exclusive. In the wild-type EpoR homodimer, both monomers
are capable of binding Epo site 1 and site 2. (B) Epo is bound to a functional EpoR heterodimer
formed from a pair of mutant EpoRs each specific for binding at only Epo site 1 or site 2. The site
1-null mutant EpoR (S 1 EpoR) containing mutations H 114K and E 117K binds only to Epo at site
2, while the site 2-null mutant EpoR (S2- EpoR) containing mutation M150E binds only to Epo at
site 1. When S - and S2- EpoRs form a heterodimer on the cell surface, they should bind Epo in a
specific manner as shown above and behave as a functional receptor capable of activation and
signaling. The emphasized side chains on each monomer are important for binding to Epo at each
site, and are mutated (not shown) on the opposite monomer. (C) Location of EpoR residues
Hisl 14 and Glul 17 in site 1 and site 2 of the Epo-EpoR complex. His 114 is shown in red,
Glu 117 is shown in blue. Both residues interact directly with Epo at the site 1 interface but are at
the periphery of the site 2 interface. Mutation of His 114 has been previously shown to
significantly weaken binding by several-fold. Glu 117 forms a salt bridge with Epo residue
Argl50 at site 1. (D) Location of EpoR residue M150 in site 1 and site 2 of the Epo-EpoR
complex. M150, shown in green, forms intricate hydrophobic packing interactions with Epo
residues at site 2, but not at site 1. M 150 is present within the interfacial regions of both sites, but
it is much more buried upon binding at site 2.
Computational Analysis of Candidate Site 1 EpoR Mutants
?
Figure ic shows the locations of His 114 and Glul 17 in the asymmetric 1-
ligand:2-receptor complex; they interact directly with Epo at the site 1 interface but are at
the periphery of the site 2 interface. Table 1 shows the computed change in the Epo-EpoR
binding free energy, relative to wild-type EpoR, as a result of mutating either His 114 or
Glul 17 to other amino acids at site 1 and leaving site 2 unaltered. For both residues,
mutation to either of the basic amino acids Lys or Arg yields the highest computed
disruption in binding affinity, over 3.0 kcal/mol in both cases. The primary mechanism of
disruption is via unfavorable electrostatic interactions, as shown in Table 1. Interestingly,
mutation of Glul 17 to any other amino acid considered was predicted to be unfavorable,
a result suggesting that an acidic residue at position 117 is important for binding Epo.
Structural analysis supports this conclusion, as Glul 17 forms a salt bridge with Epo
Arg 150.
Because the Epo-EpoR interaction at site 1 is high-affinity, more than one
mutation might be necessary to ensure defective binding. Table 2 shows the predicted
change in binding free energy for mutating both His 114 and Glul 17 to pairs of residues
that were individually promising. Because of the relative proximity of the two residues,
the changes in binding free energy of the double mutants at site 1 was not the sum of the
individual contributions shown in Table 1. For these promising double mutants, we also
considered the effect of the mutations on receptor binding at site 2. As Table 2 shows,
mutating both Hisl 14 and Glul 17 to basic residues was predicted to abrogate site 1
binding without greatly affecting site 2 binding. In this analysis we considered a binding
free energy change of greater than +3.0 kcal/mol to be significant, based on previous
experimentally-tested designs (Radhakrishnan 2007). Of these four predictions, we chose
to experimentally synthesize the H114K / E117K double EpoR mutant. In comparing the
repacked crystal structure of wild-type EpoR site 1 to the double mutant, both His114 and
Glul 17 interact with ArglS0 on Epo. Mutation of these groups to lysines is predicted to
be highly destabilizing electrostatically because it puts multiple positively charged groups
across the interface from one another. Thus we expect that the EpoR H114K / E117K
mutant will disrupt site 1 binding and allow only for binding to site 2 on Epo.
H114 E117 M150
Total Elec vdW Total Elec vdW Total Elec vdW
A 1.3 -1.3 2.5 2.5 2.6 0.0 6.1 1.4 4.6
D 0.0 -2.1 2.0 1.5 1.4 0.2 6.4 4.5 1.8
E -0.1 -2.3 2.0 - - - 6.4 5.6 0.8
F -1.6 0.1 -1.7 2.8 3.1 -0.2 30.4* 1.8 28.6
H - - - 2.6 2.5 0.1 4.9 4.0 0.9
I -1.6 3.1 -4.9 2.3 3.1 -0.8 3.3 0.1 3.1
K 3.1 1.8 1.3 4.4 4.7 -0.1 24.6 14.6 9.9
L 0.7 -1.2 1.8 2.3 4.0 -1.6 5.3 -0.6 5.8
M 0.9 -0.8 1.6 1.3 2.9 -1.6 - - -
N 0.5 -1.5 1.8 2.7 2.7 0.1 2.7 0.1 2.5Q 1.0 -0.9 1.8 2.2 2.4 -0.1 3.6 3.9 -0.3
R 3.1 2.4 0.7 3.8 4.6 -0.6 11.8 10.3 1.4
S 1.5 -0.7 2.1 2.5 2.5 0.1 6.0 1.8 4.0
T 2.4 0.3 2.0 1.9 2.5 -0.6 3.5 -0.6 4.0
V -0.8 3.1 -4.2 2.0 2.7 -0.6 4.0 -0.4 4.3
W -0.9 1.0 -1.9 2.3 2.3 0.1 54.3* 3.7 50.6
Y 0.9 2.5 -1.6 2.2 2.3 -0.1 44.1* 0.2 43.9
*Because van der Waals interactions are very sensitive to small movements in side chains, we hypothesized
that the extremely high binding free energy changes for mutations to Phe, Tyr and Trp could be relieved by
backbone and side-chain relaxations not modeled within the discrete search. Indeed, these high energy
changes disappeared when computed structures were allowed to minimize after the discrete packing (data
not shown).
Table 1. Computed change in Epo-EpoR binding free energy in kcal/mol, relative to
wild-type EpoR, for mutants at either EpoR Hisll4 or Glull7 at the site 1 interface,
or Metl50 at the site 2 interface. For site 1 mutations, site 2 was left intact during
calculations, and vice versa. The letters in the left-most column represent the amino acid of the
resulting mutation at either position 114, 117, or 150 on EpoR. Along with the total change in
binding free energy, the electrostatic (Elec) component and the van der Waals component (vdW)
of the total free energy change are also shown. Positive values of free energy change are
indicative of unfavorable interactions relative to wild-type EpoR, while negative values represent
favorable interactions.
Computational Analysis of Site 2 Mutant EpoR Candidates
Figure id shows the locations of Metl50 in the two EpoR monomers of the
asymmetric complex. At the site 2 interfaces, Met 50 interacts with multiple Epo
residues in a hydrophobic region. At site 1, Metl50 does not directly make close contacts
with Epo but is still within 5.0 A of multiple Epo residues. Table 1 shows the predicted
change in Epo-EpoR binding free energy, relative to wild-type EpoR, upon mutation of
Metl 50 at the site 2, leaving site I unmutated. In Table 2, site 1 calculations are shown
for those mutations predicted to disrupt site 2 binding. The mutations fall into two
classes. The first class included mutation to bulky, aromatic residues, Phe, Trp, and Tyr,
which cause disruption by unfavorable van der Waals interactions. However, these
unfavorable interactions might be relieved with modest relaxation and thus were not ideal
candidates. The second class of disruptive mutations altered the charge of the side chain:
Asp, Glu, Lys, and Arg. Because electrostatic effects are less amendable to relaxation,
these predictions were considered more robust, and selections were made from among
them for experimental testing.
We chose the EpoR M150E site 2 mutant for experimental synthesis and analysis,
as it was predicted to significantly disrupt binding at site 2 with no significant effect at
site 1 (Table 2). The predicted mutant structures at the site 1 and site 2 interfaces show
that at site 1, mutation to Glu allows for potential long-range electrostatic interactions
with Arg162 on Epo, and loses only minor packing interactions with Epo residues. At site
2, however, the mutation to Glu is disruptive. In our calculations the negative charge
remains buried, although other conformational possibilities are also unfavorable.
Binding to Epo Site 1 Binding to Epo Site 2
Site 1 Candidates Total Elec vdW Total Elec vdW
H114K + E117K 10.7 11.0 -0.2 0.7 0.9 -0.2
H114K + E117R 10.3 10.7 -0.3 0.4 0.7 -0.2
H114R + E117K 11.0 11.3 -0.2 0.4 0.9 -0.5
H114R + E117R 11.3 12.0 -0.6 0.3 0.8 -0.5
Site 2 Candidates
M150D 1.2 -1.0 1.8 6.4 4.5 1.8
M150E 0.0 -1.2 1.0 6.4 5.6 0.8
M150F -1.1 0.1 -1.1 30.4* 1.8 28.6
M150K 4.5 5.7 -1.0 24.6 14.6 9.9
M150R 2.7 5.6 -2.8 11.8 10.3 1.4
M150W -3.2 1.4 -4.3 54.3* 3.7 50.6
M150Y -1.0 1.1 -1.9 44.1* 0.2 43.9
*The extremely high binding free energy changes for mutations to Phe, T,
computed structures were allowed to minimize after the discrete packing.
yr and Trp disappeared when
Table 2. Comparison of site 1 and site 2 computed change in Epo-EpoR binding free
energy in kcallmol, relative to wild-type EpoR, for candidate site 1-null and site 2-
null EpoR mutants. For site 1 mutations, site 2 was left intact during calculations, and vice
versa. Along with the total change in binding free energy, the electrostatic (Elec) component and
the van der Waals component (vdW) of the total energy change are also shown. Positive values of
free energy change are indicative of unfavorable interactions relative to wild-type EpoR, while
negative values represent favorable interactions. An ideal candidate mutant has a large positive
value at the primary site of interaction (site 1 for H114 and E117, site 2 for M150) and a value
close to zero at the other site.
Validation of Mutant EpoR Candidates in Ba/F3 Cells
Based on our computational predictions we selected the human EpoR double
mutant H114K / E117K (which we will hence forth call S1- EpoR) predicted to be
deficient in site 1 binding and the single mutant M150E (S2- EpoR) predicted to be
deficient in site 2 binding for experimental validation. We hypothesized that if both
mutant receptors were deficient in binding as predicted, then expression of either mutant
in cell culture would not elicit a response to Epo stimulation, whereas co-expression of
both receptors could lead to a reconstitution of response to Epo, based on the formation
of functional receptor heterodimers (Figure lb). In such a scheme, expression of either
mutant alone results in the formation of homodimers on the cell surface of monomers
either both deficient in site 1 binding (S1/S1) or in site 2 binding (S2-/S2), and thus
unable to form a 2 receptor complex with Epo. On the other hand, when the mutants are
co-expressed, formation of heterodimers (Sl /S2) would lead to pairs with a site 1
deficient monomer that still has an intact site 2, and a site 2 deficient monomer that has
an intact site 1, thus providing the means for the heterodimeric EpoR to bind to Epo in a
specific manner.
Figure 2a shows the Epo-dependent proliferation of Ba/F3 cells expressing either
wild-type EpoR, S1 EpoR, S2- EpoR, or co-expressing both S1- EpoR and S2- EpoRs. As
expected, cells expressing either the S1- EpoR or S2 EpoRs did not proliferate in
response to any Epo concentration tested, similar to control Ba/F3 cells not expressing
any EpoR. Importantly, and as we anticipated, cells co-expressing EpoR S 1- and EpoR
S2- exhibited an Epo growth response comparable to cells expressing wild-type EpoR.
Western blotting shows similar levels of wild type, SY1 EpoR, and S2- EpoRs
(Figure 2c). FACS analysis of surface expression of EpoR using an antibody specific for
the HA epitope tag appended to the extracellular N-terminus of EpoR (Figure 2b) shows
comparable surface expression levels of wild-type, SI-, and S2- EpoRs. Thus lack of
proliferation of Ba/F3 cells expressing only EpoR S 1 or S2- mutant EpoRs is not due to
reduced cell surface expression of the mutant receptors.
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Figure 2. Co-expression of S1- and S2 EpoR mutants in Ba/F3 cells restores
concentration-dependent proliferation in response to Epo. (A) Assay for proliferative
response of EpoRs to Epo stimulation. Ba/F3 cells expressing various EpoRs were cultured at
50,000 cells/ml in RPMI media containing 10% FBS and varying concentrations of Epo (0.01,0.1, 1, and 10 units/ml). Relative viable cell density was measured using an MTT assay in
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duplicate after 72 hours of growth. Data are represented as mean +/- standard deviation. (B)
Surface expression of wild-type and mutant EpoRs. FACS analysis was performed on Ba/F3 cells
expressing wild-type or mutant HA-tagged EpoR in an IRES-GFP containing vector. Whole cells
were stained with mouse ac-HA monoclonal primary antibody followed by APC-tagged goat Ca-
mouse secondary antibody to probe for surface receptors. GFP versus APC signal is plotted, with
medians as shown. (C) Overall expression of EpoRs as assayed by Western blotting. Ba/F3 cells
expressing various EpoRs were grown in IL-3-containing media, then harvested and lysed for
SDS-PAGE. EpoR was detected with rabbit polyclonal a-EpoR antibody.
Epo Binding Affinity of Mutant Epo Receptors
To test the effect of the computationally selected mutations in EpoR on Epo
binding, we measured equilibrium binding of 125I-Epo to the surface of Ba/F3 cells
expressing wild-type, S V, or S2- EpoR (Figure 3). Analysis of Epo binding to Ba/F3-
wild-type EpoR cells indicated there were -2,100 surface Epo binding sites per cell [Bmax
= 3.54 fmoles/10 6 cells (95% conf. interval: 3.47, 3.61)], with KD = 0.14 nM (95% conf.
interval: 0.13, 0.15), which is similar to previous measurements of the affinity of Epo for
cell surface EpoR. Although Ba/F3-Sr1 EpoR and Ba/F3-S2- EpoR cells expressed
similar amounts of HA-tagged EpoR protein on the cell surface compared to Ba/F3-wild-
type EpoR cells (Figure 2b), Epo bound with a lower affinity to cells expressing the
mutant receptors (Figure 3). Ba/F3-S 1 cells specifically bound only a very small amount
of Epo compared to wild-type EpoR cells; binding was so low that the KD for the S -
EpoR could not be reliably determined. Ba/F3-S2- cells bound Epo with a reduced, but
measurable, KD = 0.9 nM (95% conf. interval: 0.6, 1.2). Given that Epo site I has a much
higher binding affinity for EpoR than Epo site 2 (Philo et al. 1996), the above results
suggest that, as predicted, the mutations in the S - EpoR disrupt high affinity Epo site 1
binding, and the mutations in the S2- EpoR disrupt low affinity Epo site 2 binding.
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Figure 3. Epo-binding by wild-type or mutant EpoRs. Equilibrium binding of 1'25I-Epo to
the surface of parental Ba/F3 cells (no EpoR) or Ba/F3 cells expressing wild-type or S1- or S2-
mutant EpoR was measured. Binding to parental Ba/F3 cells (no EpoR) represents non-specific
binding. Bound and free 125I-Epo was measured and binding curves fitted through the plotted data
points as described in Experimental Procedures. Estimated dissociation constants are as follows:
wild-type EpoR - 0.14 nM, S1- EpoR - 77 nM, and S2- EpoR - 0.90 nM.
Hydrophobic Switch Residues on Either Receptor Monomer Contribute Equally to
EpoR Activation
Three conserved hydrophobic residues in thejuxtamembrane cytosolic domain of
EpoR, L253, 1257, and W258, are necessary for the activation of the associated JAK2.
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Mutating any of these residues to alanine in the EpoR homodimer dramatically
suppresses growth and signaling responses to Epo stimulation but does not affect the
ability of the Epo receptors to bind Jak2, traffic normally to the cell surface, or bind Epo
(Constantinescu, Huang et al. 2001). Here we ask whether these switch residues have a
greater contribution to EpoR activation when they are present on the site 1 or site 2-
binding EpoR monomer. In the experiments described in Figure 4, we studied both S1-
and S2- EpoRs that had either the L253A or W258A mutation.
Figure 4a shows that having the inactivating L253A mutation on either monomer,
but the normal L253 on the other, does not abrogate the proliferative response to Epo, but
rather reduces the growth response at Epo concentrations between 0.01-1.0 units/ml; this
is true whether the L253A mutation is present on the Sl-binding EpoR: Sl- EpoR
expressed together with S2- EpoR L253A, or on the S2-binding receptor: S1- EpoR
L253A expressed together with S2- EpoR. The maximal growth response is similar to that
of wild-type EpoR at a saturating concentration of 10 units/ml. Surface expression of the
L253A EpoR mutants is approximately 1/3 of wild-type EpoR (data not shown), and
therefore likely accounts for some of the reduced response to Epo stimulation. As
expected cells expressing mutant EpoRs in which the L253A mutation is present in both
monomers, S1- EpoR L253A and S2- EpoR L253A, do not proliferate in the presence of
Epo.
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Figure 4. Conserved hydrophobic residues are needed only on one monomer of
EpoR to achieve a proliferative response to Epo. (A) L253A mutation on either EpoR
monomer causes symmetric partial impairment of response to Epo stimulation. Ba/F3 cells
expressing various EpoRs were cultured at 50,000 cells/ml in RPMI media containing 10% FBS
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and varying concentrations of Epo (0.01, 0.1, 1, and 10 units/ml). Relative viable cell density was
measured with MTT assay performed in duplicate after 72 hours of growth. Data are represented
as mean +/- standard deviation. (B) W258A mutation on either EpoR monomer causes symmetric
partial impairment of response to Epo stimulation. Ba/F3 cells expressing various EpoRs were
cultured at 50,000 cells/ml in RPMI media containing 10% FBS and varying concentrations of
Epo (0.01, 0.1, 1, and 10 units/ml). Relative viable cell density was measured with MTT assay
performed in duplicate after 72 hours of growth. Data are represented as mean +/- standard
deviation.
Similar results were obtained by mutating another conserved hydrophobic residue,
W258, to alanine. Figure 4b shows that having the inactivating mutation W258A on
either monomer but the normal W258 residue on the other allows proliferation in
response to Epo, but -10-fold higher Epo concentrations are required compared to cells
expressing SY and S2- EpoRs both with a tryptophan at position 258. This is true whether
the W258A mutation is present on the S1-binding EpoR: S1- EpoR expressed together
with S2- EpoR W258A or whether it is present on the other monomer, S1- EpoR W258A
expressed together with S2- EpoR. As expected, cells expressing mutant EpoRs in which
the W258A mutation is present in both monomers, S1- EpoR W258A and S2- EpoR
W258A, do not proliferate in the presence of Epo. Surface expression of S1- EpoR
W258A and S2- EpoR W258A mutants was about half that of wild-type EpoR (data not
shown). That mutating W258 to alanine has a greater effect than mutating L253 was
expected; mutation of W258 to alanine in otherwise wild-type EpoR inhibits JAK2
phosphorylation completely, whereas EpoR L253A exhibits very low levels of JAK2
activation compared to wild-type EpoR (Constantinescu, Huang et al. 2001).
Taken together, these results show that the critical L253 and W258 residues need
be present on only one EpoR in the heterodimeric 1 Epo: 2 EpoR complex in order to
activate signaling and proliferation in Ba/F3 cells. The contribution of these residues is
the same regardless of which monomer they reside on.
A single tyrosine, Y343, on either the site 1-defective or the site 2-defective EpoR is
sufficient to support Epo-dependent cell proliferation and StatS activation.
Of the eight conserved tyrosines on the cytoplasmic tail of EpoR that become
phosphorylated following JAK2 activation, phospho-Y343 is specific for binding the
Stat5 SH2 domain, resulting in phosphorylation of Stat5 by JAK2 (Damen, Wakao et al.
1995). Activated Stat5 then dimerizes in the cytoplasm and translocates into the nucleus
to act as a transcription factor for various genes suppressing apoptosis and promoting
proliferation and differentiation (Socolovsky et al. 1999). A truncated EpoR containing
only amino acids 1-375 (EpoR-H), and retaining only the first phosphorylated tyrosine of
the cytoplasmic tail (Y343), supports Epo-triggered proliferation when expressed in IL3-
dependent cells (Miura et al. 1991). Mutation of Y343 to phenylalanine in EpoR-H,
called EpoR-H Y343F, abolished the ability of EpoR-H to activate Stat5 and significantly
depressed the ability of the EpoR to support cell proliferation, indicating the importance
of phosphoY343 and Stat5 activation in EpoR signaling and cell survival (Li et al. 2003).
To test whether a single phosphorylated tyrosine, Y343, was sufficient if present on
either the site 1-defective or the site 2-defective EpoR, we first constructed and tested
two truncated EpoRs, one defective in site 1 binding and the other defective in binding
Epo site 2, called S1- EpoR-H and S2- EpoR-H. Figure 5a shows that cells expressing
both truncated EpoRs together, S1- EpoR-H and S2- EpoR-H, supported Epo- dependent
cell proliferation similar to cells expressing two full- length EpoRs, S1- EpoR and S2-
EpoR. Cell surface expression analysis by FACS indicated a nearly two-fold higher
surface expression of the truncated EpoRs compared to full-length receptors (data not
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Figure 5. Truncated EpoR with one Tyr343 is sufficient for proliferation in response
to Epo stimulation. All H and H Y343F mutants are truncated EpoRs containing only the first
375 amino acids from the N terminus. (A) Full-length wild-type EpoR is compared to full-length
heterodimeric EpoR (Sl- / S2-), truncated wild-type EpoR 1-375 (EpoR-H), and truncated
C
heterodimeric EpoR 1-375 (S -H/S2 H) in a proliferation assay to assess truncated EpoR
response to Epo. Ba/F3 cells expressing various EpoRs were cultured at 50,000 cells/ml in RPMI
media containing 10% FBS and varying concentrations of Epo (0.01, 0.1, 1, and 10 units/ml).
Relative viable cell density measured with MTT assay performed in duplicate after 72 hours of
growth. Data are represented as mean +/- standard deviation. (B) Y343 is only needed on one
partner in a truncated EpoR dimer for proliferation in response to Epo stimulation. Ba/F3 cells
expressing various EpoRs were cultured at 50,000 cells/ml in RPMI media containing 10% FBS
and varying concentrations of Epo (0.01, 0.1, 1, and 10 units/ml). Relative viable cell density
measured with MTT assay performed in duplicate after 72 hours of growth. Data are represented
as mean +/- standard deviation. (C) Heterodimeric EpoR with only one Y343 residue on either
monomer is capable of signaling via Stat5 phosphorylation. Ba/F3 cells expressing the various
EpoRs were washed and starved for 4 hours at 37*C in RPMI media containing 1% BSA. They
were stimulated with Epo at either 0, 1, or 10 units/ml for 10 minutes at room temperature.
Stimulation was stopped with excess cold PBS, and cells were pelleted for lysis and Western
blotting. Phospho-Stat5 was detected with rabbit a-pStat5 (pTyr694) antibody.
shown). As expected, cells expressing either S1- EpoR-H or S2- EpoR-H alone showed
no growth response to Epo (Figure 5b).
The experiments in Figures 5b and 5c show directly that a single tyrosine, Y343,
on either the Site 1-defective or the Site 2-defective EpoR, is sufficient to support Epo-
dependent cell proliferation and Stat5 activation. Cells co-expressing S1 EpoR-H
together with S2- EpoR-H Y343F, in which the single tyrosine Y343 is present only on
the site 2- binding EpoR monomer, exhibited a growth response to Epo (Figure 5b) and
Epo- dependent activation of Stat5 (Figure 5c) similar to that of cells co-expressing
mutant EpoRs in which Y343 is present both on the site 1-binding and the site 2-binding
EpoR monomer, S2- EpoR-H and S1- EpoR-H, respectively. Similarly, cells co-
expressing S1- EpoR-H Y343F together with S2- EpoR-H, in which Y343 is present only
on the site 1-binding EpoR monomer, also exhibited a normal growth response to Epo
(Figure 5b) and Epo- dependent activation of Stat5 (Figure 5c).
Thus the location of the single (phospho) tyrosine Y343, whether on the site 1-
binding or site 2-binding receptor monomer, does not impact the proliferative response to
Epo. Both S1- EpoR-H Y343F expressed together with S2- EpoR-H, and S1 EpoR-H
expressed together with S2- EpoR-H Y343F, have nearly identical response curves to Epo
stimulation. As controls, Ba/F3 cells expressing either S1- EpoR-H, S2- EpoR-H, S1-
EpoR-H Y343F , or S2- EpoR-H Y343F , or co-expressing the tyrosine-null pair S1-
EpoR-H Y343F and S2- EpoR-H Y343F have little to no proliferative response to Epo
(Figure 5b) or ability to support Epo-triggered activation of Stat5 (Figure 5c).
Collectively, these results show that the Y343 residue in the EpoR cytoplasmic tail,
sufficient for sustaining mitogenic activity in Ba/F3 cells, is only necessary on one
monomer of the EpoR dimer to allow signaling through the receptor and activation of
Stat5. Thus, our results suggest that both receptors are competent for signaling, and we
suggest that the receptors signal equally.
Discussion
The erythropoietin receptor is one of several cytokine receptors that
homodimerize and bind to two discrete sites on a monomeric ligand (Frank 2002). Here
we have analyzed the amino acid residues on EpoR that bind to these different sites on
Epo. Despite a significant overlap in the EpoR residues that make up each binding site,
we were able to computationally identify key EpoR residues necessary for specific
binding to Epo site 1 and site 2. We generated two mutants: one, termed S -, that is
deficient in binding to Epo site 1 but not site 2, and one, termed S2-, that is deficient in
binding to site 2 but not site 1. We showed that each of these mutants has the expected
properties when expressed in cultured Ba/F3 cells, through the use of Epo-dependent
proliferation assays and determination of KD values via equilibrium binding to Epo. More
importantly, we showed that when the S 1 EpoR and S2- EpoR are co-expressed, the
proliferative response to Epo stimulation is similar to that of wild-type EpoR, indicating
functional complementation by the two mutant receptors and signaling by Epo-activated
SI- / S2- EpoR heterodimers. Using our EpoR mutants we showed that the conserved
juxtamembrane hydrophobic residues L253 and W258, essential for Jak2 activation, as
well as the intracellular tyrosine Y343 are only needed on one monomer of an EpoR
dimer (regardless of which side) to permit activation and signaling in response to Epo.
This study illustrates the potential of using computational protein design to create
research reagents with properties designed to facilitate experimental investigation of
complex biological systems.
Rational Design
Here we assumed mutations at either site 1 or site 2 produced only local structural
change and used computational design to search over mutant sequences and
conformations while repacking side chains in the local neighborhood. This is likely to be
a good assumption for the well packed interfacial interactions in this ternary protein
complex.
The structural data suggested that EpoR M150 primarily interacts with Epo site 2
and not with Epo site 1. EpoR M150 does interact with the aliphatic portion of Epo RO1
at the site 2 interface. However, the R10 rotamer chosen for the lowest energy repacked
wild type and S2- mutant were identical, so the predicted AAG's were likely due to
localized site 2 effects, and not effects transduced through altered conformations of
residue R10.
Previous experiments demonstrated that an EpoR M150A mutant was only
slightly less responsive to Epo than wild-type EpoR (Middleton et al. 1999). As shown in
Table 1, our initial predictions showed a significant loss of affinity at site 2 with an
M150A mutation, although the cost was primarily in the van der Waals component of
binding and could be relieved through structural relaxation. Moreover, the predicted
binding free energy using the other neutral tautomer of H 153 was approximately 1.5
kcal/mol more favorable than the one shown in Table 1. Minimizing structures
corresponding to both H153 tautomers yielded structures predicted to bind approximately
3.2-5.5 kcal/mol worse than wild type on average, again with the van der Waals energy
being the primary difference. On the other hand, both tautomers of the M 150E mutant
were predicted to bind to Epo site 2 greater than 6 kcal/mol worse than wild type. With
the binding energy mainly stemming from electrostatic contributions, which are less
amenable to relaxation, these predictions are likely to be more robust. Therefore,
although our methods may still be overestimating the loss of binding due to an alanine
mutation, the predictions are consistent with the idea that an alanine substitution at EpoR
M150 can affect site 2 binding, but not as much as the M150E mutant.
Functional Activation of the EpoR Heterodimer
We then generated site 1-deficient and site 2-deficient EpoR mutants and showed
that they behave as predicted. The results from the proliferation assay and the Stat5
signaling assay both confirm that our mutants are unable to activate and signal when
expressed alone. The S 1- EpoR and S2- EpoR mutants expressed alone have a weak
response to Epo stimulation at very high concentrations of 10 U/ml in both the
proliferation and Stat5 signaling assays, suggesting that although our mutations strongly
disrupt site 1 and site 2 function, they do not completely abrogate binding at high Epo
concentrations. However, for the purposes of our study, the lack of response to Epo
stimulation at physiologic Epo concentrations of 1 U/ml or less is sufficient for assuming
that these receptors are nonfunctional when expressed by themselves.
More importantly, when we co-expressed our mutant S 1 EpoR and S2 EpoR in
the same cells, we saw signaling and proliferation in response to stimulation at
physiologic Epo concentrations, validating our computational design of a functional
heterodimeric EpoR. These experiments also establish that our EpoR mutations target
two distinct aspects of the receptor, in this case binding to Epo site 1 and site 2, such that
the two mutant receptors can complement one another to restore a normal receptor
response. Because these mutant receptors are expressed normally on the cell surface, it is
unlikely that these mutations interfere with proper folding or intracellular trafficking of
the receptors. We assume that when S1 EpoR and S2- EpoR are co-expressed, both
homodimers and heterodimers will form in the absence of Epo, but only heterodimers can
be activated by Epo stimulation. The formation of non-signaling homodimers (S - / S -
EpoR and S2- / S2- EpoR) in cells co-expressing both mutant receptors condition likely
explains why the "EpoR S1r / S2- Ba/F3 strains exhibit a slightly weaker response to Epo
when compared to wild-type EpoR.
Epo Binding Affinities of Mutant EpoRs
The binding of a single ligand to two cytokine receptor monomers through the use
of two distinct receptor binding sites with different binding affinities was first shown in
the human growth hormone (hGH) interaction with its receptor (hGHbp) (Cunningham et
al. 1991). The human growth hormone receptor binds to two discrete sites -- site 1 and
site 2 on the monomeric hGh ligand. This differs from other receptors such as EGFR that
dimerize by binding to a pair of identical homodimerized ligands. The fact that a single
binding KD is found for both hGH-hGHbp and Epo-EpoR binding suggests that receptor
dimerization is occurring on the cell surface. Biophysical measurements showed that this
1-ligand:2-receptor interaction is mediated by two receptor binding sites on Epo -- a
high affinity site 1 and a low affinity site 2 (Philo et al. 1996).
Our equilibrium binding data is consistent with Philo et al.'s site 1 KD value,
because both the wild-type EpoR and the S2- EpoR (the mutant still able to bind to Epo
site 1) have a KD value for wild-type Epo of -1nM. The KD for the S2- EpoR is slightly
higher than that of the wild-type EpoR; presumably this is because wild-type EpoR can
bind Epo at both site 1 and site 2 whereas the S2- mutant can bind only to site 1 on Epo.
Our S 1 EpoR, which is predicted to be deficient in binding to Epo site 1, shows little or
no specific binding to Epo, which is also consistent with our predictions. The equilibrium
binding assay is only useful for measuring the site 1 binding affinity, as Epo site 1 has a
thousand-fold higher affinity for the EpoR extracellular domain than site 2, whose
affinity cannot be meaningfully measured in this manner(Philo et al. 1996). Our S2-
EpoR mutant can be compared to the G120R hGH mutant that blocks site 2 binding to the
growth hormone receptor. This GH mutant acts as an antagonist to the hGH-hGHbp
complex formation by binding to site 1 only and preventing receptor dimerization (Fuh et
al. 1992). The difference is that our M150E mutation is made in the receptor, but this
mutation also prevents ligand binding to site 2 and therefore prevents Epo from forming a
receptor dimer in a conformation appropriate for receptor activation.
Hydrophobic Switch Residues and Tyrosine Phosphorylation
We previously proposed a model where the conserved cytosolic juxtamembrane
hydrophobic residues, L253, 1257, and W258 facilitate the release of kinase-inhibitory
interactions between the JH2 and JH1 domains of the JAK2 molecule appended to the
EpoR cytosolic domain (Lu et al. 2008). The JAK2 JH2 pseudokinase domain normally
acts as a negative regulatory element that, through physical interaction in the absence of
ligand stimulation, keeps the JH 1 kinase domain in an inactive state (Saharinen et al.
2000). Mutation of EpoR residues L253, 1257, or W258 to alanine leads to loss of JAK2
activation by Epo (Constantinescu, Huang et al. 2001), but these hydrophobic residues
are not needed for the constitutive activation of the JAK2V617F mutant. The V617F
mutation lies on one of the two principal interfaces between the JH 1 and JH2 domains
(Lu et al. 2008), suggesting that the function of L253, 1257, and W258 may be to disrupt
the interaction between the JH2 and JH1 domains to facilitate JAK2 activation.
However, we do not know whether Jak2 activation is in cis or trans. That is, we
do not know whether the conserved L253, 1257, and W258 residues activate the Jak2
bound to the same EpoR or the opposite one, or possibly both. Here, we showed that
these hydrophobic residues need only to be present on one side of the EpoR dimer to
support signaling. In particular we see an Epo-dependent proliferative effect on cells with
EpoR possessing L253 or W258 on one monomer only. These results suggest (but do not
prove) that only one kinase-active JAK2 is necessary for successful EpoR signaling,
albeit at reduced efficiency.
We also showed that only one tyrosine, Y343, is needed on an EpoR dimer to
support signaling. Y343 must be phosphorylated by an activated JAK2 on the EpoR
before it can recruit downstream signaling molecules, but we do not know whether Jak2
phosphorylates tyrosines on the EpoR cytosolic domain in cis or trans. That is, we do not
know whether Jak2 phosphorylates tyrosines on the receptor to which it is bound or the
opposite one, or possibly both.
Studies on EGF and FGF receptors indicate that the tyrosine kinases linked to
these dimeric receptors are capable of intermolecular transphosphorylation, shown
through the expression of kinase-active mutant receptors that are able to phosphorylate
tyrosines on kinase-negative mutant receptors (Lammers et al. 1990; Bellot et al. 1991).
Another example is found in the EGF receptor family members HER2 and HER3, both of
which are incapable of being activated through ligand stimulation, as HER2 lacks the
ability to couple to the downstream signaling cascade while HER3 lacks the kinase
activity to phosphorylate cytoplasmic tyrosines. Only when they are co-expressed can
HER2 and HER3 heterodimerize and activate downstream signaling pathways,
suggesting that transphosphorylation must be taking place in this receptor dimer as well
(Holbro et al. 2003). Our EpoR mutants may be useful in studying EpoR auto- or
transphosphorylation as they allow us to generate kinase-dead and tyrosine to
phenylalanine mutants that may be used to show the cis or trans relationship between the
conserved juxtamembrane hydrophobic residues, the appended JAK2 proteins, and the
EpoR tyrosines that become phosphorylated.
Experimental Procedures
Preparation of Epo-EpoR Structure
Studies were initiated using the 1.9-A crystal structure of Epo complexed with the
extracellular portion of EpoR (PDB ID 1EER) (Syed et al. 1998). Flipping of asparagine,
glutamine, and histidine residues and removal of most crystallographic water molecules
was done as explained in (Lippow et al. 2007). Each of the 41 retained water molecules
was assigned by inspection to either the ligand binding partner or the receptor binding
partner. The HBUILD facility (Brunger et al. 1988) in the CHARMM software package
(Brooks et al. 1983) was used to build all hydrogen-atom positions. CHARMM was also
used to build the missing side-chain density of Epo residue Arg166 and to terminate the
main chain at Asp8 and Thr220 on both EpoR chains with acetamide and N-methylamide
groups, respectively, as residues 0-7 and 221-226 of each monomer were not located in
the crystal structure experiment. The PARAM22 all-atom parameter set (MacKerell et al.
1998) and the CHARMM-adapted TIP3P water model (Jorgensen et al. 1983) were used.
The crystallized proteins in this structure differ in sequence from wild-type proteins at
multiple positions (on Epo: N24K, N38K, N83K, P121N, P122S; on EpoR monomers:
N52Q, N164Q, A211E), all of which were at least 9.0 A (and generally much farther)
from the closest residue on a binding partner. In addition, the naturally occurring
oligosaccharides present on both Epo and EpoR were not modeled, as they were absent
from the crystal structure (due to mutated asparagines). In this work, we refer to this
model system as wild-type, and we assume that the relative binding free energies of
mutation in this system are not significantly different from that of the naturally-occurring
wild-type proteins.
Computational Mutation Analysis
The two-stage hierarchical' approach of Lippow et al. (2007) was used to calculate
binding free energies of mutants. In the first stage, a conformational search over discrete
rotamers for mobile and mutated side chains was done to determine stable conformations
of the mutated bound states. All side chains (excluding prolines) and crystallographic
water molecules containing atoms within 5.0 A of the native side chain(s) to be mutated
were considered mobile in the repacking calculations, and the backbone was considered
rigid. A pairwise energy function was used to evaluate structures and the determination of
the global minimum energy structure and the next 29 other lowest-energy structures. All
energies used in the combinatorial search were computed using the all-atom
CHARMM22 force field (MacKerell et al. 1998). Binding was considered rigid; the
unbound states were not repacked separately.
In the second stage, the binding and folding free energy of each of the 30 lowest-
energy structures for each mutant was re-evaluated using a more accurate energy function
that replaced the electrostatics term in the first stage with a continuum electrostatic
treatment using the linearized Poisson-Boltzmann equation (LPBE) (Gilson et al. 1987;
Gilson et al. 1988; Sharp et al. 1990) with the PARSE parameters (Sitkoff et al. 1994)
and added a nonpolar solvation term that was proportional to solvent-accessible surface
area (Lippow et al. 2007). One translation of a 257x257x257 grid was used for
numerically solving for electrostatic potentials, corresponding to approximately 3 grid
units/A. The predicted binding free energy for each mutant or wild-type structure with the
lowest bound-state energy was used to calculate the AAGbind values shown here.
Additionally, to assess the robustness of the results for predictions aimed to
disrupt binding (H 114 and E 117 at site 1, and M 150 at site 2), conformations for
promising mutants and the repacked wild type were energy minimized. Residues that
were mobile in the repacking were considered mobile in the minimization, and the
corresponding backbone atoms were also minimized. Local minimizations were carried
out using the adapted-basis Newton-Raphson method in CHARMM, using a tolerance of
<lx10 -7 kcal/mol and a distance-dependent dielectric constant of 4. Binding free energies
were then calculated from these minimized structures.
Cloning of human EpoR variants
The retroviral vector pMX-IRES-GFP with hemagglutinin epitope (HA)-tagged
human EpoR cDNA cloned upstream of the internal ribosome entry site (IRES)-green
fluorescent protein (GFP) sequences was a gift from Dr. S.N. Constantinescu (Ludwig
Institute for Cancer Research, Brussels, Belgium). The pBI-CD4 vector was kindly
provided by Dr. Christopher Hug (Whitehead Institute for Biomedical Research). The site
1 EpoR double mutant (S1- EpoR H114K/E117K) was generated by mutating the CAC
codon for histidine 114 of EpoR to AAG for lysine, and the GAA codon for glutamic
acid 117 of EpoR to AAA encoding lysine using site-directed mutagenesis as described
by the Quickchange strategy (Stratagene). For the site 2 EpoR mutant (S2- EpoR
M150E), the AUG codon for methionine 150 of EpoR was mutated to AAG encoding
glutamic acid using the same method as in site 1. To generate the L253A and W238A site
1 and site 2 hEpoR mutants, the S1 and S2- pMX-HA-hEpoR-IRES-GFP constructs were
used for site-directed mutagenesis via the Quickchange strategy. The CTG codon for
leucine 253 or the TGG codon for tryptophan 258 was changed to GCG (alanine) in each
respective mutant.
The truncated hEpoR constructs (EpoR-H) were made using the wild-type pMX-
HA-hEpoR-GFP construct described above as template. PCR reactions were performed
using primers annealed to the BamHI site before the start of the HA-hEpoR sequence and
to the region at hEpoR amino acid 375, with the addition of a stop codon followed by an
EcoRI restriction site inserted after the sequence for alanine 375. The purified PCR
products were digested with BamHI and EcoRI, then purified again before ligating into
the original pMX-HA-hEpoR-IRES-GFP vector digested with BamHI and EcoRI to
remove the full-length HA-hEpoR sequence. To obtain the site 1 and site 2 mutant
variants (S1- EpoR H, S2- EpoR H) of these truncated EpoR constructs, S1- and S2- HA-
hEpoR inserts were excised from pMX-HA-hEpoR-GFP using BglII restriction sites, and
ligated into the truncated wild type EpoR-H pMX-GFP construct also digested with
BglII, to replace the wild-type hEpoR sequence with the mutant sequences for S 1 and
S2-. To generate EpoR-H constructs containing a Y343F mutation, site-directed
mutagenesis via the Quickchange strategy was used on the truncated EpoR-H constructs.
To subclone all the above various EpoR constructs into a pBI-CD4 vector for co-
expression, BamHI and NotI restriction sites were used to excise the wild-type and
mutant HA-hEpoR sequences from the pMX-IRES-GFP vectors for ligation into the pBI-
CD4 backbone.
Expression of EpoR in Tissue Culture Cells
Retroviral vectors carrying wild-type and mutant EpoR cDNAs were transfected
into 293T cells along with the pCL-Eco packaging vector, using FuGENE6 transfection
reagent (Roche). Supernatant containing retroviruses were collected after 48 hours. Ba/F3
cells were grown in RPMI 1640 with 10% fetal bovine serum (FBS), 1% penicillin-
streptomycin, 1% L-glutamine, and 6% WEHI-3B cell conditioned medium as a source
of IL-3. To stably express wild-type or mutant EpoRs in Ba/F3 cells, retrovirus
supernatants were used for spin-infection of Ba/F3 parental cells. For co-expressing two
different EpoR mutants, 50% of each supernatant (one for the pMX-GFP cDNA and one
for the pBI-CD4 cDNA) was used to maintain the total viral load. Two days after spin-
infection, about 90% of the Ba/F3 cells were GFP positive. For single expressions, all the
GFP positive cells were collected with FACS, and for co-expressions, GFP and CD4
double positive cells were collected with FACS.
Surface and Overall EpoR Expression Analysis
To measure surface HA-tagged hEpoR protein, in-tact Ba/F3 cells were stained
with mouse anti-HA primary antibody (Covance Research Products, Inc., Berkeley, CA,
monoclonal HA.11, clone 16B12) and then with an allophycocyanin (APC)-conjugated
goat anti-mouse Ig secondary antibody (BD Biosciences, San Jose, CA). Flow cytometry
measurements were made on a FACSCalibur machine, and data were analyzed with
CellQuest software (Becton Dickinson, San Jose, CA) to measure the median
fluorescence intensities for GFP and APC. Relative overall expression of hEpoR in Ba/F3
cells was determined by Western blotting. Ba/F3 cells expressing various hEpoRs were
grown in RPMI with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, 1% L-
glutamine, and 6% WEHI-3B cell conditioned medium as a source of IL-3. They were
harvested and lysed with RIPA buffer (50mM Tris pH 7.5, 150mM NaCi, 1% NP-40,
0.5% sodium deoxycholate, 0.1% SDS) for SDS-PAGE. For Western blotting, hEpoR
was detected with rabbit polyclonal anti-hEpoR antibody (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, EpoR antibody M-20).
Determination of Binding Affinity
Recombinant human erythropoietin (Epo) (a gift from Amgen Inc., Thousand
Oaks, CA) was labeled with Iodine-125 (Perkin Elmer, NEN, Boston, MA) using Iodo-
Gen reagent (Pierce Biotechnology, Rockford, IL). '25I-Epo specific activity was
routinely - 4 x 106 cpm/pmole, representing an average of one 125I atom incorporated per
molecule of Epo. To measure binding affinity, binding medium (fresh Ba/F3 culture
medium without any WEHI-3B cell conditioned medium) was equilibrated to atmosphere
in a 4VC room and the pH was adjusted to 7.3. Ba/F3 cells expressing various EpoRs
were incubated in binding medium with 125I-Epo for 18 hours at 4VC. Bound and free
125I-Epo were separated by centrifuging cells through a layer of FBS. Non-specific
binding was measured with parental Ba/F3 cells which lack detectable Epo-specific
binding sites on their surface (Gross et al. 2006). KD and Bm, were determined by fitting
the model for a single-class of non-cooperative binding sites to data obtained over a range
of ligand concentrations, using MATLAB software (The Mathworks, Inc., Natick, MA).
Proliferation and MTT Assays
IL-3-dependent Ba/F3 parental cells or Ba/F3 cells expressing wild-type or
mutant EpoRs were washed and resuspended at 50,000 cells/ml in RPMI with 10% FBS,
1% L-glutamine, and recombinant human Epo (Amgen) at a range of specified
concentrations. After three days, 100ul of well-mixed culture from each well was
removed in duplicate for a 96-well format MTT assay to determine cell viability and
growth, according to established protocols (Promega Corporation, Madison, WI). The
signal from the MTT assay was measured as absorbance at 570nm using a 96-well plate
reader.
Phosphorylation Signaling Assays
Ba/F3 cells expressing various hEpoRs were washed and resuspended at 1x10 6
cells/ml in RPMI with 1% BSA, then starved for 4 hours at 37°C. After starvation, cells
were stimulated with a range of specified Epo concentrations in RPMI with 1% BSA for
10 minutes at room temperature. Excess cold phosphate buffered saline (PBS) was added
to stop stimulation, followed by pelleting of cells. Pellets were lysed in modified RIPA
buffer (50mM Tris pH 7.5, 150mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1mM
Na 3VO4, 5mM NaF) for SDS-PAGE and Western blotting. Phosphorylated Stat5 was
detected with polyclonal rabbit anti-phosphoStat5 (pY694) antibody (Cell Signaling
Technology, Inc., Danvers, MA).
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